|
|
Post by nimrod71 on Sept 30, 2016 7:53:33 GMT -5
Scripts down week ending 9/23 can't wait to hear the plethora of excuses.
|
|
|
|
Post by mnkdfann on Sept 30, 2016 8:01:57 GMT -5
Scripts down week ending 9/23 can't wait to hear the plethora of excuses. Symphony's database is mixed up and the numbers being reported are really in hexadecimal. You'll see! |
|
|
|
Post by dictatorsaurus on Sept 30, 2016 8:04:48 GMT -5
Weather starting to get cold. Less people leaving their bedrooms.
|
|
|
|
Post by bioexec25 on Sept 30, 2016 8:18:49 GMT -5
Scripts down week ending 9/23 can't wait to hear the plethora of excuses. Symphony's database is mixed up and the numbers being reported are really in hexadecimal. You'll see! Nice one. Hex would be F7. Perhaps they are in Octal which would be 367. Better yet they are in Base 4 which would be 3313. Now we're talking. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 30, 2016 8:30:27 GMT -5
Jay Olson hacked symphonys data base so MNKD longs would be scared into to selling their shares.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 30, 2016 8:38:15 GMT -5
Yep .. I am waiting too to see if any reason is factual
|
|
|
|
Post by kbrion77 on Sept 30, 2016 8:41:32 GMT -5
Jay Olson hacked symphonys data base so MNKD longs would be scared into to selling their shares. Don't worry we will get a post soon reiterating Symphony and IMS are owned by Hedge Funds and the conspiracy to destroy MNKD continues. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 30, 2016 8:51:04 GMT -5
Jay Olson hacked symphonys data base so MNKD longs would be scared into to selling their shares. Don't worry we will get a post soon reiterating Symphony and IMS are owned by Hedge Funds and the conspiracy to destroy MNKD continues. I think I believed that one at one point lol |
|
|
|
Post by als57 on Sept 30, 2016 9:56:31 GMT -5
Every week we get closer to our ordained end. There is very limited forward progress as pushing endo buy-in seems to be without traction.
|
|
|
|
Post by straightly on Sept 30, 2016 10:04:11 GMT -5
Every week we get closer to our ordained end. There is very limited forward progress as pushing endo buy-in seems to be without traction. All hopes are not lost, but risk increased. When the doc campaign comes, it's do or die with a short runway. |
|
|
|
Post by mockingjay on Sept 30, 2016 10:13:07 GMT -5
without words
|
|
|
|
Post by gonetotown on Sept 30, 2016 10:14:47 GMT -5
What is happening with the reps? After over three months in the field selling the drug they should have some feel from the response they're getting from doctors as to where things are heading. Has there been any feedback from them?
|
|
|
|
Post by gonetotown on Sept 30, 2016 10:18:34 GMT -5
Every week we get closer to our ordained end. There is very limited forward progress as pushing endo buy-in seems to be without traction. All hopes are not lost, but risk increased. When the doc campaign comes, it's do or die with a short runway. Maybe not, but everytime I look at MNKD the phrase, "Lasciate ogne speranza, voi ch'intrate," seems to flash across the screen. |
|
|
|
Post by peppy on Sept 30, 2016 10:24:19 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 30, 2016 10:32:57 GMT -5
under the heading too little too late. consider; what if the designation, ultra rapid is given afrezza. ? Some of the meta analysis post 2016 are calling afrezza ultra rapid mealtime insulin. The designation is already being used. Peppy, if the Ultra rapid designation comes soon, take me through the sequence of events which you believe would need to take place and how they would impact Afrezza and Mannkind. Also please comment how long the sequence of events would take. Ultra means a new category but for the payors who have exclusive deals for a RAA, are they in the short term going to push back on their vendors? From another perspective, how long until MNKD reps can pitch a superior clinical value proposition to physicians and other healthcare professionals (within FDA regs)? Lastly, what kind of DTC could MNKD use to tell patients the clinical benefits of Ultra Rapid acting (again within FDA regs). Not trying to be a spoil sport, but without a significant infusion of cash, time is no longer our friend. Ultra rapid designation could be a powerful tool but it would be some time until it could be monitized, No? |
|
